Non-Infective Inflammatory Bone Marrow Disease

Author(s):  
Bernhard J. Tins ◽  
Victor N. Cassar-Pullicino
2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Ahmed G. Elsayed ◽  
Aeesha Ranavaya ◽  
Muhammad Omer Jamil

Essential thrombocythemia (ET) is a clonal bone marrow disease, characterized by increased production of platelets along with other clinical and bone marrow findings. Most patients with ET will have a somatic mutation in one of the known gene locations of JAK2, CALR , or MPL that can upregulate the JAK-STAT pathway. MPL mutation is present in 5% of cases with the most common mutations being W515L and W515K. In this report we describe 2 cases of patients with clinical and laboratory picture of ET. One patient carried MPLY252H mutation which is previously unreported in the adult population but has been shown to be a gain-of-function mutation. The other patient carried MPL F126fs mutation which is not known to be of clinical importance and has not been previously reported.


Blood ◽  
1972 ◽  
Vol 40 (3) ◽  
pp. 353-365 ◽  
Author(s):  
Raymond Alexanian ◽  
Judith Nadell ◽  
Clarence Alfrey

Abstract Oxymetholone was given to 28 adults with chronic anemia from bone marrow disease. Changes in hematocrit and red cell mass were correlated with serial assessments of erythropoietin and erythropoiesis. Erythropoietin excretion was enhanced more than five-fold over the level expected for the hematocrit in 70% of the patients. Only 23% of the patients with an evaluable treatment trial increased their red cell mass by at least 20%. In all responders, the T½ of 59Fe disappearance ranged from 86-136 min and erythron iron turnover exceeded 0.25 mg/100 ml blood/day. A decline in serum iron concentration to the 50-100 µg/100 ml range after 1 mo of oxymetholone was frequently associated with a subsequent response to therapy. Patients with severe bone marrow failure, for whom frequent red cell transfusions were required, did not improve. The failure of other patients to respond was attributed to complicating factors that either impaired maximal erythropoietin production or restricted iron supply to the bone marrow. Hepatic toxicity was detected in less than 10% of treated patients. Results support the use of oxymetholone in the treatment of patients with moderate degrees of bone marrow failure and symptomatic anemia.


1991 ◽  
Vol 20 (2) ◽  
pp. 79-84 ◽  
Author(s):  
S. L. Hanna ◽  
B. D. Fletcher ◽  
D. L. Fairclough ◽  
J. H. Jenkins ◽  
A. H. Le

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2190-2190
Author(s):  
Karlijn Stouten ◽  
Jurgen A Riedl ◽  
Mark-David Levin

Abstract Introduction Macrocytic anaemia (MCV ≥ 100 fl) is regularly encountered in general practice and in hospital settings. However, the incidence of macrocytic anaemia in newly diagnosed patients remains elusive. In addition, factors influencing laboratory diagnosis and prognosis are unclear. PAGAS (Project of Anaemia from the General practitioner to the Albert Schweitzer hospital) is a collaboration of 63 general practitioners and the Albert Schweitzer hospital (Dordrecht, the Netherlands), which aims at improving quality of care for anaemic patients. We set out to clarify the incidence of newly discovered macrocytic anaemia in the PAGAS cohort and to determine the underlying causes of macrocytic anaemia. Methods Anaemia was defined as a haemoglobin level below 13.7 g/dL for men and below 12.1 g/dL for women. These values were used for persons older than 16 years. Patients who were included in the PAGAS study had to present to their general practitioner with a newly diagnosed anaemia i.e. no known anaemia in the preceding two years. Women were included when aged 50 years or older, in order to prevent an overabundance of iron deficiency anaemia (IDA) due to hypermenorrhea. Men were included when aged 17 or older. Patients were included between the 1st of February 2007 and the 1st of February 2013. For each patient an extensive laboratory work-up was performed, considering a broad range of causes of anaemia. Furthermore all additional hospital work-up was analyzed as well, including bone marrow examinations and a report of alcohol abuse when present. A classification system was developed that included the following causes: 1) anaemia of chronic disease (ACD 2) haemolysis 3) bone marrow disease 4) vitamin B12 deficiency 5) folic acid deficiency 6) iron deficiency 7) reported alcohol abuse 8) renal anaemia and 9) other. If no cause could be established, it was classified as unknown. The cause of each anaemia was established by 2 independent observers. In case of a discrepancy, the observers deliberated until a consensus was reached. Results Over the span of 6 years a total of 2738 patients were included in the PAGAS study. 190 (6,9%) of these 2738 patients presented with a macrocytic anaemia; 108 men (56,8%) and 82 (43,2%) women. Men were aged 70,7 years on average at the time of inclusion while women had an average age of 79 years when included. In 83,7% of patients (N=159), the underlying cause of the anaemia could be established. Seven patients displayed a double underlying cause. Bone marrow disease was found 18 times (9,1%), vitamin B12 deficiency 27 times (13,7%), folic acid deficiency 10 times (5,1%), haemolysis 7 times (3,6%) and alcohol abuse 27 times (13,7%). In addition, we found 39 patients (19,8%) with ACD, 4 patients (2,0%) with IDA and 29 patients (14,7%) with renal anaemia. Five cases of anaemia (2,5%) were classified as other. Overall survival was 57 months (95% CI 52,6-61,4) after entry into the study. The survival of patients with a nutrient deficiency, vitamin B12 or folic acid, was significantly shorter (41,8 months, 95% CI 33,2-50,3) when compared to the survival of the other patients in the cohort (58,3 months, 95% CI 53,7-63) (p-value = 0,024). See figure 1. Significantly more alcohol abuse was found as a cause in the age group of 50-64 years (20 of 27 cases) compared to the other four age groups (17-49, 65-74, 75-84 and 85+ years) combined (p-value = 0,000). In addition, the number of cases of renal anaemia found in the combined 75-84 and 85+ age groups (27 of 29 cases) differed significantly when compared to the other three age groups combined (p-value = 0,000). Nutrient deficiency was observed more often in the two highest age groups combined (24 of 37 cases) when compared to the lower three combined but this difference was not significant (p-value = 0,165). Discussion In our cohort study the well known causes of macrocytic anaemia – bone marrow disease, alcohol abuse, haemolysis and vitamin B12 and folic acid deficiency – were found in 45,2% of patients. However, ACD, IDA and renal anaemia, typically reported in normocytic and microcytic anaemic patients, were leading causes of anaemia in 36,5% of patients. As shown in our population the causes of macrocytic anaemia are diverse. Therefore we consider a broad diagnostic work-up warranted to completely elucidate the underlying cause. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5348-5348
Author(s):  
Moussab Damlaj ◽  
Giamal Edin Mohamed Gmati ◽  
Ghulam Syed ◽  
Mohsen Al Zahrani ◽  
Khadega Ahmed Abuelgasim ◽  
...  

Abstract Background: Routine bone marrow biopsy (BMB) for the initial staging of Hodgkin Lymphoma (HL) is not recommended in the era of FDG-PET/CT staging (J Clin Oncol. 2014;32(27):3059). However, patients from the Middle East and North Africa (MENA) region have epidemiologic and clinical features of lymphoma that are different from patients of other ethnicities (J Natl Compr Canc Net2010;8:S-29-S-35). Therefore, it is unknown whetherFDG-PET/CT can substitute for staging BMB in this population.At our center, we perform routine BMB for all newly diagnosed lymphoma cases. Aim: To investigate whether routine BMB is essential in detecting bone marrow disease where FDG-PET/CT is used in initial staging for HL in patients from the MENA region. Methods: Patients with HL at our institution between 2010 - 2015 were identified. Inclusion criteria included newly diagnosed patients who had BMB and FDG-PET/CT as part of initial staging. All baseline and laboratory features were retrospectively extracted. Pathology reports of bone marrow aspirate and trephine biopsies were reviewed by two independent Hematologists. All written FDG-PET/CT reports were retrieved and carefully reviewed and cases with positive skeletal uptake were re-interpreted by an experienced radiologist. Pattern of skeletal FDG-PET/CT uptake was determined and classified as unifocal or multifocal. Sensitivity and specificity was computed while defining bone marrow disease by positive BMB and / or focal skeletal uptake on FDG-PET/CT. Categorical and continuous variables were analyzed using Pearson's chi-squared and Student's t-test, respectively. Results: A. Baseline characteristics: A total of92 patients met the inclusion criteria and were considered for this analysis. All patients were from the MENA region and > 90% were from the Arabian peninsula. From this cohort, bone marrow disease was detected in 7 (7.6%) patients using BMB while 20 (21.7%) patients had unifocal or multifocal bone marrow uptake on FDG-PET/CT. An additional 21 patients (23%) had diffuse homogenous FDG uptake and was not considered to represent HL. The cohort was characterized by a male to female ratio of 1.4 and a median age at diagnosis of 27 years (6-83). About two thirds of the cases were classical HL of the nodular sclerosis subtype (Table 1). Almost 60% of cases were stage III - IV with corresponding median IPS of 2 (0-6). Incidence of bulky disease and B-symptoms among the entire cohort was 32% and 50%, respectively. B. Comparison of FDG-PET/CT and BMB No patient with involved BMB (iBMB) had early stage disease on FDG-PET/CT and BMB identified only one patient with positive BM involvement yet negative skeletal uptake on FED-PET/CT. Involvement by BMB upstaged 3 patients previously assessed by CT scan as having stage III, however, none of the patients were allocated to a different treatment plan based on the BMB result. On the other hand, FDG-PET/CT upstaged 24 patients (26%); 9 patients from stage III to IV and 14 patients from early to advanced stage resulting in change of therapeutic plan in the latter group. Focal skeletal FDG-PET/CT lesions identified positive marrow disease with a sensitivity and specificity of 95.2% and 70.4%, respectively. On the other hand, sensitivity and specificity of BMB was 35% and 100%, respectively (Table 2). Abnormal skeletal FDG uptake was seen in a total of 20 patients (21.7%); 11 (55%) had unifocal / bifocal while 9 (45%) had multifocal disease of the axial skeleton. Patients with iBMB compared to those with negative BMB but positive unifocal / multifocal skeletal FDG-PET/CT lesions were more likely to be male (p = 0.002), have B-symptoms (p = 0.028), extranodal disease (p = 0.017) and more likely to have multifocal uptake on FDG-PET/CT (0.017) (Table 3). Conclusion:To our knowledge, this is the first analysis to examine the role of FDG-PET/CT for detection of bone marrow involvement in HL in a patient cohort from the MENA region. We observed that FDG-PET/CT had a higher sensitivity and negative predictive value compared to BMB leading to a treatment change in a significant proportion of patients. This analysis highlightsthat FDG-PET/CT can substitute for BMB in routine staging for newly diagnosed patients with HL from the MENA region. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2000 ◽  
Vol 96 (10) ◽  
pp. 3374-3380 ◽  
Author(s):  
Ruben A. Mesa ◽  
Curtis A. Hanson ◽  
S. Vincent Rajkumar ◽  
Georgene Schroeder ◽  
Ayalew Tefferi

Abstract Recent observations have underscored the biologic relevance of intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow angiogenesis has been demonstrated in a variety of hematologic disorders, including multiple myeloma. The extent and prognostic significance of bone marrow angiogenesis in 114 patients with myelofibrosis with myeloid metaplasia (MMM) was investigated. A control group of 44 patients without bone marrow disease, 15 patients with polycythemia vera, and 17 patients with essential thrombocythemia was also studied. Bone marrow microvessel density was assessed by a semiquantitative method, visual microvessel grading, and 2 separate quantitative methods, visual count and computerized image analysis. Angiogenesis estimation by all 3 methods was highly comparable. On visual microvessel grading, a grade 3 or 4 increase in bone marrow angiogenesis was demonstrated in 70% of patients with MMM, 33% of patients with polycythemia vera, 12% of patients with essential thrombocythemia, and 0% of normal controls. In a multivariate analysis, increased angiogenesis in MMM correlated significantly with increased spleen size and was found to be a significant and independent risk factor for overall survival. Increases in marrow angiogenesis correlated with hypercellularity and megakaryocyte clumping. In contrast, these 2 features were inversely proportional to reticulin fibrosis, whereas increases in marrow angiogenesis were independent of reticulin fibrosis. These preliminary findings suggest that neo-angiogenesis is an integral component of the bone marrow stromal reaction in MMM and may provide useful prognostic information and a rationale for the therapeutic investigation of anti-angiogenic agents.


2017 ◽  
Vol 72 ◽  
pp. S143
Author(s):  
A. Druy ◽  
E. Shorikov ◽  
G. Tsaur ◽  
A. Popov ◽  
S. Tuponogov ◽  
...  

Radiology ◽  
1984 ◽  
Vol 151 (3) ◽  
pp. 715-718 ◽  
Author(s):  
M D Cohen ◽  
E C Klatte ◽  
R Baehner ◽  
J A Smith ◽  
P Martin-Simmerman ◽  
...  

2014 ◽  
Vol 111 (2) ◽  
pp. S74
Author(s):  
Giuliano Mariani ◽  
Paola A. Erba ◽  
Marzio Perri ◽  
Martina Sollini ◽  
Elena Lazzeri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document